Expression of Epstein-Barr Virus-encoded Latent Membrane Protein (LMP-1), p16 and p53 Proteins in Nonendemic Nasopharyngeal Carcinoma (NPC): AClinicopathological Study

Archives of Medical Research

Volumn 45, Issue 3, 2014, Pages 229-236

  Rosales Pérez, Samuel ^a   Cano Valdez, Ana M ^b   Flores Balcázar, Christian H ^b   Guedea Edo, Ferran ^c   Lino Silva, Leonardo S ^b   Lozano Borbalas, Alicia ^c   Navarro Martín, Arturo ^c   Poitevin Chacón, Adela ^d  

^a HOSPITAL DE ONCOLOGÍA   (Mexico)

^b INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d Medica Sur Hospital   (Mexico)

Author keywords

EBV LMP1; Immunohistochemistry; Nasopharyngeal carcinoma; P16; P53

Indexed keywords

CISPLATIN; FLUOROURACIL; GEMCITABINE; LATENT MEMBRANE PROTEIN 1; PROTEIN P16; PROTEIN P53;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; EPSTEIN BARR VIRUS INFECTION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; METASTASIS POTENTIAL; NASOPHARYNX CARCINOMA; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; RADIATION RESPONSE; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR INVASION; TUMOR RECURRENCE;

EBV-LMP1; IMMUNOHISTOCHEMISTRY; NASOPHARYNGEAL CARCINOMA; P16; P53;

ADULT; AGED; CARCINOMA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; SEX FACTORS; TUMOR SUPPRESSOR PROTEIN P53; VIRAL MATRIX PROTEINS; YOUNG ADULT;

EID: 84899520166     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2014.02.002     Document Type: Article

References (44)

1. Sham J.S., Wei W.I., Zong Y.S., et al. Detection of subclinical nasopharyngeal carcinoma by fiber optic endoscopy and multiple biopsy. Lancet 1990, 335:371-374.
2. Yu M.C., Yuan J.M. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 2002, 12:421-429.
3. Parkin D.M., Muir C.S. Cancer incidence in five continents. Comparability and quality of data 1992, 120:45-173. IARC Scientific Publications, Lyon.
4. Brennan B. Nasopharyngeal carcinoma. Orphanet J Rare Dis 2006, 1:23.
5. Vasef M.A., Ferlito A., Weiss L.M. Nasopharyngeal carcinoma, with emphasis on its relationship to Epstein-Barr virus. Ann Otol Rhinol Laryngol 1997, 106:348-356.
6. Johansen L.V., Mestre M., Overgaard J. Carcinoma of the nasopharynx. Analysis of treatment results in 167 consecutively admitted patients. Head Neck 1992, 14:200-207.
7. Chang J.T., Ko J.Y., Hong R.L. Recent advances in the treatment of nasopharyngeal carcinoma. J Formosan Med Assoc 2004, 103:496-510.
8. Sanguineti G., Geara F.B., Garden A.S., et al. Carcinoma of the nasopharynx treated by radiotherapy alone. Determinants of local and regional control. Int J Radiat Oncol Biol Phys 1997, 37:985-996.
9. Al-Sarraf M., LeBlanc M., Giri P.G., et al. Chemoradiotherapy vs. radiotherapy in patients with advanced nasopharyngeal cáncer: phase III randomized Intergroup study 0099. J Clin Oncol 1998, 16:1310-1317.
10. Razak A.R., Siu L.L., Liu F.F., et al. Nasopharyngeal carcinoma: the next challenges. Eur J Cancer 2010, 46:1967-1978.
11. Tsao S.W., Tramoutanis G., Dawson C.W., et al. The significance of LMP1 expression in nasopharyngeal carcinoma. Semin Cancer Biol 2002, 12:473-487.
12. Wilson J.B., Weinberg W., Johnson R., et al. Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6. Cell 1990, 61:1315-1317.
13. Morris M.A., Dawson C.W., Wei W., et al. Epstein-Barr virus-encoded LMP1 induces a hyperproliferative and inflammatory gene expression programme in cultured keratinocytes. J Gen Virol 2008, 89:2806-2820.
14. Morris M.A., Dawson C.W., Young L.S. Role of the Epstein-Barr virus-encoded latent membrane protein 1, LMP1, in the pathogenesis of nasopharyngeal carcinoma. Future Oncol 2009, 5:811-825.
15. Dawson C.W., Port R.J., Young L.S. The role of the EBV-encoded latentmembrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). Semin Cancer Biol 2012, 22:144-153.
16. Chan J.K., Quintanilla-Martinez L., Ferry J.A., et al. World Health Organization classification of tumors of haematopoietic and lymphoid tissues 2008, 285-288. IARC Press.
17. Greene F.L., Page D.L., Fleming I.D., et al. The AJCC Cancer Staging Manual 2002, Springer, Berlin. 6th ed.
18. Busson P., Ooka T., Corbex M. Nasopharyngeal carcinomas and Epstein-Barr virus: from epidemiology and detection to therapy. Med Sci (Paris) 2004, 20:453-457.
19. Ou S.H., Zell J.A., Ziogas A., et al. Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology. Ann Oncol 2007, 18:29-35.
20. Wenig B.M. Nasopharyngeal carcinoma. Ann Diagn Pathol 1999, 3:374-385.
21. Vokes E.E., Liebowitz D.N., Weichselbaum R.R. Nasopharyngeal carcinoma. Lancet 1997, 350:1087-1091.
22. Reddy S.P., Raslan W.F., Gooneratne S., et al. Prognostic significance of keratinization in nasopharyngeal carcinoma. Am J Otolaryngol 1995, 16:103-108.
23. Cheung F., Chan O., Tong-Ng W., et al. The prognostic value of histological typing in nasopharyngeal carcinoma. Oral Oncol 2012, 48:429-433.
24. Shi W., Pataki I., MacMillan C., et al. Molecular pathology parameters in human nasopharyngeal carcinoma. Cancer 2002, 94:1997-2006.
25. Yip K.W., Shi W., Pintilie M., et al. Prognostic significance of the Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal cancer. Clin Cancer Res 2006, 12:5726-5732.
26. Spratt D.E., Lee N. Current and emerging treatment options for nasopharyngeal carcinoma. OncoTargets Therapy 2012, 5:297-308.
27. Middeldorp J.M., Pegtel D.M. Multiple roles of LMP1 in Epstein-Barr virus induced immune escape. Semin Cancer Biol 2008, 18:388-396.
28. Li J., Zhang X.S., Xie D., et al. Expression of immune-related molecules in primary EBV-positive Chinese nasopharyngeal carcinoma: associated with latent membrane protein 1 (LMP1). Cancer Biol Ther 2007, 6:1997-2004.
29. Lauritzen A.F., Hording U., Nielsen H.W. Epstein-Barr virus and Hodgkin's disease: a comparative immunological, in situ hybridization, and polymerase chain reaction study. APMIS 1994, 102:495-500.
30. Qi Z.L., Han X.Q., Hu J., et al. Comparison of three methods for the detection of Epstein-Barr virus in Hodgkin's lymphoma in paraffin-embedded tissues. Mol Med Rep 2013, 7:89-92.
31. Li X., Liu X., Ding Y., et al. Recombinant adeno-associated virus mediated RNA interference inhibits metastasis of nasopharyngeal cancer cells invivo and invitro by suppression of Epstein-Barr virus encoded LMP-1. Int J Oncol 2006, 29:595-603.
32. Hariwiyanto B., Sastrowiyoto S., Mubarika S., et al. LMP1 and LMP2 may be prognostic factors for outcome of therapy in nasopharyngeal cancers in Indonesia. Asian Pac J Cancer Prev 2010, 11:763-766.
33. Kondo S., Wakisaka N., Schell M.J., et al. Epstein-Barr virus latent membrane protein 1 induces the matrix metalloproteinase-1 promoter via an Ets binding site formed by a single nucleotide polymorphism: enhanced susceptibility to nasopharyngeal carcinoma. Int J Cancer 2005, 115:368-376.
34. Hu L.F., Chen F., Zhen Q.F., et al. Differences in the growth pattern and clinical course of EBV LMP1 expressing and non-expressing nasopharyngeal carcinomas. Eur J Cancer 1995, 31:658-660.
35. Jeon Y.K., Lee B.Y., Kim J.E., et al. Molecular characterization of Epstein-Barr virus and oncoprotein expression in nasopharyngeal carcinoma in Korea. Head Neck 2004, 26:573-583.
36. Zhao Y., Wang Y., Zeng S., et al. LMP1 expression is positively associated with metastasis of nasopharyngeal carcinoma: evidence from a meta-analysis. J Clin Pathol 2012, 65:41-45.
37. Ho H.C., Lee M.S., Hsiao S.H., et al. Prognostic influence of parapharyngeal extension in nasopharyngeal carcinoma. Acta Otolaryngol 2008, 128:790-798.
38. Lu Z.X., Ma W.Q., Yang L.F., et al. DNAzymes targeted to EBV-encoded latent membrane protein-1 induce apoptosis and enhance radiosensitivity in nasopharyngeal carcinoma. Cancer Lett 2008, 265:226-238.
39. Ma X., Yang L., Xiao L., et al. Down-regulation of EBV-LMP1 radio-sensitizes nasal pharyngeal carcinoma cells via NF-κB regulated ATM expression. PLoS One 2011, 6:e24647.
40. Baba Y., Tsukuda M., Mochimatsu I., et al. Reduced expression of p16 and p27 proteins in nasopharyngeal carcinoma. Cancer Detect Prev 2001, 25:414-419.
41. Rocco J.W., Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res 2001, 264:42-55.
42. Shiga K., Ogawa T., Katagiri K., et al. Differences between oral cancer and cancers of the pharynx and larynx on a molecular level. Oncol Lett 2012, 3:238-243.
43. Shibosawa E., Tsutsumi K., Koizuka I., et al. Absence of nuclear p16 from Epstein-Barr virus-associated undifferentiated nasopharyngeal carcinomas. Laryngoscope 2000, 110:93-97.
44. Xiang Y.N., Zhang W.Y. The clinical significance of p16 protein non-expression and p16 gene inactivation by deletions and hypermethylation in nasopharyngeal carcinoma. Zhonghua Bing Li Xue Za Zhi 2005, 34:358-361.